{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:27:04Z","timestamp":1780118824551,"version":"3.54.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.tranon.2021.101048","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T19:11:20Z","timestamp":1614712280000},"page":"101048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia"],"prefix":"10.1016","volume":"14","author":[{"given":"Priscilla","family":"Wander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5858-4174","authenticated-orcid":false,"given":"Susan T.C.J.M.","family":"Arentsen-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6748-5554","authenticated-orcid":false,"given":"Sandra S.","family":"Pinhan\u04abos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Emmy M.","family":"Dolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-1292","authenticated-orcid":false,"given":"Rijndert","family":"Ariese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-8330","authenticated-orcid":false,"given":"Frank L.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Garrido","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5207-3349","authenticated-orcid":false,"given":"Luke","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Guillen","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-1656","authenticated-orcid":false,"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2021.101048_bib0001","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate","volume":"29","author":"Abrahamsson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101048_bib0002","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2010.08107.x","article-title":"Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses","volume":"149","author":"Creutzig","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2021.101048_bib0003","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial","volume":"155","author":"Gibson","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2021.101048_bib0004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2021.101048_bib0005","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","article-title":"Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese childhood AML cooperative study group","volume":"27","author":"Tsukimoto","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101048_bib0006","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101048_bib0007","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101048_bib0008","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101048_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5045\/br.2018.53.1.1","article-title":"Current treatment for pediatric acute myeloid leukemia","volume":"53","author":"Im","year":"2018","journal-title":"Blood Res."},{"key":"10.1016\/j.tranon.2021.101048_bib0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nrd1900","article-title":"Finding new tricks for old drugs: an efficient route for public-sector drug discovery","volume":"4","author":"O'Connor","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tranon.2021.101048_bib0011","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/bjc.1994.446","article-title":"Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay","volume":"70","author":"Kaspers","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2021.101048_bib0012","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/bjc.1989.44","article-title":"Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia","volume":"59","author":"Pieters","year":"1989","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2021.101048_bib0013","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V76.11.2327.2327","article-title":"In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions","volume":"76","author":"Pieters","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101048_bib0014","doi-asserted-by":"crossref","first-page":"33769","DOI":"10.18632\/oncotarget.5615","article-title":"Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration","volume":"6","author":"Xiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2021.101048_bib0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tranon.2021.101048_bib0016","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.tranon.2021.101048_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40272-016-0200-6","article-title":"Current management of childhood acute myeloid leukemia","volume":"19","author":"Rubnitz","year":"2017","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.tranon.2021.101048_bib0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101048_bib0019","article-title":"The role of HDACs inhibitors in childhood and adolescence acute leukemias","volume":"2011","author":"Masetti","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.tranon.2021.101048_bib0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2174\/156802609789895728","article-title":"Update on Hsp90 inhibitors in clinical trial","volume":"9","author":"Kim","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.tranon.2021.101048_bib0021","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/jcp.26006","article-title":"The novel role of pyrvinium in cancer therapy","volume":"233","author":"Momtazi-Borojeni","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tranon.2021.101048_bib0022","first-page":"5871","article-title":"Anthelmintic pyrvinium pamoate blocks Wnt\/beta-catenin and induces apoptosis in multiple myeloma cells","volume":"15","author":"Xu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2021.101048_bib0023","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2015.12.059","article-title":"Pyrvinium selectively induces apoptosis of lymphoma cells through impairing mitochondrial functions and JAK2\/STAT5","volume":"469","author":"Xiao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tranon.2021.101048_bib0024","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2011.12.034","article-title":"Pyrvinium pamoate inhibits proliferation of myeloma\/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3","volume":"319","author":"Harada","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2021.101048_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11095-020-2767-4","article-title":"Pyrvinium Pamoate use in a B cell acute lymphoblastic leukemia model of the bone tumor microenvironment","volume":"37","author":"Nair","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tranon.2021.101048_bib0026","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-016-0252-7","article-title":"Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia","volume":"9","author":"Feng","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2021.101048_bib0027","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55360","article-title":"beta-catenin and gamma-catenin are dispensable for T lymphocytes and AML leukemic stem cells","volume":"9","author":"Zhao","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.tranon.2021.101048_bib0028","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4269\/ajtmh.1959.8.349","article-title":"The treatment of pinworm infections in humans (enterobiasis) with pyrvinium chloride and pyrvinium pamoate","volume":"8","author":"Beck","year":"1959","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.tranon.2021.101048_bib0029","doi-asserted-by":"crossref","first-page":"e71508","DOI":"10.1371\/journal.pone.0071508","article-title":"The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tranon.2021.101048_bib0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt1976196802","article-title":"Absorption of pyrvinium pamoate","volume":"19","author":"Smith","year":"1976","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tranon.2021.101048_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127037","article-title":"Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens","volume":"30","author":"Gaikwad","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tranon.2021.101048_bib0032","doi-asserted-by":"crossref","first-page":"e3951","DOI":"10.1371\/journal.pone.0003951","article-title":"Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy","volume":"3","author":"Yu","year":"2008","journal-title":"PLoS ONE"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:40:24Z","timestamp":1761835224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1936523321000401"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101048","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101048"}}